Pharmacologic management of behavioral instability in medically ill pediatric patients

Current Opinion in Pediatrics

Volumn 16, Issue 5, 2004, Pages 516-522

  Cummings, Michael R ^a,b   Miller, Bruce D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Adolescents; Aggression; Agitation; Children; Medical illness; Medications

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DIAZEPAM; DIPHENHYDRAMINE; GUANFACINE; HALOPERIDOL; HYDROXYZINE; LORAZEPAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PROPRANOLOL; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE DISEASE; ADOLESCENT; AGITATION; ANTICHOLINERGIC EFFECT; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CHILD; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DELIRIUM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; LIVER TOXICITY; MEDICAL CARE; MORBIDITY; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; WITHDRAWAL SYNDROME;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; AGGRESSION; ANALGESICS, NON-NARCOTIC; BEHAVIOR THERAPY; BEHAVIORAL MEDICINE; BENZODIAZEPINES; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLONIDINE; DIPHENHYDRAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; LITHIUM; METHYLPHENIDATE; PSYCHOMOTOR AGITATION; VALPROIC ACID;

EID: 4644228228     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000139300.13152.20     Document Type: Review

References (37)

1. Riba M, Glick R: Acute psychiatric disorders in primary care. In Acute Care Psychiatry: Diagnosis and Treatment. Edited by Sederer LI, Rothschild AJ. Baltimore: Williams & Wilkins; 1997:67-68.
2. Ayd F: In Lexicon of Psychiatry, Neurology and the Neurosciences, 2nd ed. Edited by Michell C. Philadelphia: Lippincott Williams & Wilkins; 2000.
3. Pugh MB (ed): Stedman's Medical Dictionary, 24th ed. Baltimore: Williams & Wilkins; 1992:33.
4. Lewis D, Yeager C: Diagnostic evaluation of the violent child and adolescent. Child Adolesc Psychiatr Clin N Am 2000, 9:815-839.
5. Malone RP, Bennet DS, Luebbert JF: Aggression classification and treatment response. Psychopharmacol Bull 1998, 34:41-45.
6. Roberts R, Attkisson C, Rosenblatt A: Prevalence of psychopathy among children and adolescents. Am J Psychiatry 1998, 155:715-724.
7. Cadman D, Boyle M, Szatmar P, et al.: Chronic illness, disability, and mental social well being: findings of the Ontario Child Health Study. Pediatrics 1987, 79:805-813.
8. Brown R, Henke A, Greenhalgh D, et al.: The use of haloperidol in the agitated, critically ill pediatric patient with burns. J Burn Care Rehabil 1996, 17:34-38.
9. Masters K, Bellonci C, Burnet W, et al.: Practice parameters for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry 2002, 41 (suppl 2):S4-S25.
10. dos Reis S, Barnett S, Love R, et al.: A guide for managing acute aggressive behavior of youths in residential and inpatient treatment facilities. Psychiatr Serv 2003, 54:1357-1363. This article reviews the literature and provides treatment guidelines for the management of acute aggression in children in psychiatric inpatient or residential settings.
11. Schur SB, Sikich L, Findling R, et al. : Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), part I: a review. J Am Acad Child Adolesc Psychiatry 2003, 42:132-144. An extensive review and treatment recommendations for the evaluation and long-term management of aggression in children. It describes pharmacologie and non-pharmacologic interventions with particular attention given to antipsychotic medication.
12. Pappadopulos E, MacIntyre J, Crismon M, et al.: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), part II. J Am Acad Child Adolesc Psychiatry 2003, 42:145-161.
13. Ryan N, Bhatara V, Perel J : Mood stabilizers in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999, 38:529-536.
14. Campbell M, Small AM, Green WH, et al.: Behavior efficacy of haloperidol and lithium carbonate: a comparison of hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984, 41:650-656.
15. Campbell M, Adams PB, Small AM, et al.: Lithium in hospitalized aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 1995, 34:4445-4453.
16. Malone RP, Delaney M, Luebbert J, et al.: A double blinded placebo controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000, 57:649-654.
17. Donovan SJ, Stewart JW, Nunes EV, et al.: Divalproex treatment for youth with explosive temper and mood liability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000, 157:818-820.
18. Janiak P: Handbook of Psychopharmacotherapy. Edited by Mitchell C. Philadelphia: Lippincott Williams & Wilkins; 1999.
19. Waxmonsky J: Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 2003, 15:476-482.
20. Connor DF, Glatt SJ, Lopez ID, et al.: Psychopharmacology and aggression, 1: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002, 41:253-261.
21. Bukstein OG, Kolko DJ: Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Psychol 1998, 27:340-351.
22. Riddle M, Bernstein G, Cook E, et al.: Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999, 38:546-556.
23. Stewart JT, Myers WC, Burket R, et al.: A review of the pharmacotherapy of aggression in children and adolescents. J Am Acad Child Adolesc Psychiatry 1990, 29:269-277.
24. Lang C, Remington D: Treatment with propanolol of severe self-injurious behavior in a blind, deaf, and retarded adolescent. J Am Acad Child Adolesc Psychiatry 1994, 33:265-269.
25. Kuperman S, Stewart M: Use of propranolol to decrease aggressive outburst in younger patients. Psychosomatics 1987, 28:315-319.
26. Measham T: The acute management of aggressive behavior in hospitalized children and adolescents. Can J Psychiatry 1995, 40:330-336.
27. Schweizer E: Generalized anxiety disorder: longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 1995, 18:843-856.
28. Wudarsky M, Nicolson R, Hamburger M, et al.: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999, 9:239-245.
29. Koller E, Malozowski S, Doraiswamy P: Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001, 286:2547-2548.
30. Martin A, Landau J, Leebens P, et al.: Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000, 10:259-268.
31. Glassman A, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158:1774-1782.
32. Reliiy JG, Ayis SA, Ferrier IN, et al.: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000, 355:1048-1052.
33. Daniel DG, Potkin SG, Reeves KR, et al.: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind randomized trial. Psychopharmacology (Berl) 2001, 155:128-134.
34. Buitelaar JK: Open label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 2000, 10:19-26.
35. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al.: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive Abilities. J Clin Psychiatry 2001,62:239-248.
36. Sikich L, Hamer RM, Bashford RA, et al.: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004, 29:133-145. This is a prospective, randomized pilot study comparing atypical antipsychotics (risperidone and olanzapine) with haloperidol in psychotic children.
37. Meehan K, Zhang F, David S, et al.: A double-blind randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001, 21:389-397.